{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T21:19:34Z","timestamp":1743110374002,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":27,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071627716"},{"type":"electronic","value":"9781071627723"}],"license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-2772-3_30","type":"book-chapter","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:07:03Z","timestamp":1668794823000},"page":"557-568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Delivery of a Monoclonal Antibody to Immunologically Block Myostatin in the A17 Mouse Model of OPMD"],"prefix":"10.1007","author":[{"given":"Alberto","family":"Malerba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Harish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"Suppl 1","key":"30_CR1","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0960-8966(97)00077-1","volume":"7","author":"JP Bouchard","year":"1997","unstructured":"Bouchard JP, Brais B, Brunet D et al (1997) Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 7(Suppl 1):S22\u2013S29","journal-title":"Neuromuscul Disord"},{"issue":"17","key":"30_CR2","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1111\/febs.12294","volume":"280","author":"A Banerjee","year":"2013","unstructured":"Banerjee A, Apponi LH, Pavlath GK et al (2013) PABPN1: molecular function and muscle disease. FEBS J 280(17):4230\u20134250","journal-title":"FEBS J"},{"issue":"3","key":"30_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/NEN.0b013e3182854c07","volume":"72","author":"T Gidaro","year":"2013","unstructured":"Gidaro T, Negroni E, Perie S et al (2013) Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J Neuropathol Exp Neurol 72(3):234\u2013243","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"30_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF00692226","volume":"49","author":"FM Tome","year":"1980","unstructured":"Tome FM, Fardeau M (1980) Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 49(1):85\u201387","journal-title":"Acta Neuropathol"},{"unstructured":"Trollet C, Gidaro T, Klein P et al (1993 [updated 2014 Feb 20]) Oculopharyngeal muscular dystrophy. GeneReviews\u00ae [Internet]","key":"30_CR5"},{"key":"30_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","volume":"20","author":"SJ Lee","year":"2004","unstructured":"Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61\u201386","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"11","key":"30_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/ng.2772","volume":"45","author":"R Sartori","year":"2013","unstructured":"Sartori R, Schirwis E, Blaauw B et al (2013) BMP signaling controls muscle mass. Nat Genet 45(11):1309\u20131318","journal-title":"Nat Genet"},{"issue":"6","key":"30_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1096\/fj.04-2796com","volume":"19","author":"S Bogdanovich","year":"2005","unstructured":"Bogdanovich S, Perkins KJ, Krag TO et al (2005) Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19(6):543\u2013549","journal-title":"FASEB J"},{"issue":"4","key":"30_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK et al (2017) Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55(4):458\u2013464","journal-title":"Muscle Nerve"},{"issue":"5","key":"30_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/cpdd.386","volume":"7","author":"I Bhattacharya","year":"2018","unstructured":"Bhattacharya I, Pawlak S, Marraffino S et al (2018) Safety, tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (PF-06252616), an antimyostatin monoclonal antibody in healthy subjects. Clin Pharmacol Drug Dev 7(5):484\u2013497","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"30_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.21338","volume":"63","author":"KR Wagner","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA et al (2008) A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63(5):561\u2013571","journal-title":"Ann Neurol"},{"issue":"6914","key":"30_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, Krag TO, Barton ER et al (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420(6914):418\u2013421","journal-title":"Nature"},{"issue":"5","key":"30_CR13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1096\/fj.10-176917","volume":"25","author":"L Zhang","year":"2011","unstructured":"Zhang L, Rajan V, Lin E et al (2011) Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 25(5):1653\u20131663","journal-title":"FASEB J"},{"issue":"8","key":"30_CR14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/sj.mt.6300182","volume":"15","author":"V Siriett","year":"2007","unstructured":"Siriett V, Salerno MS, Berry C et al (2007) Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther 15(8):1463\u20131470","journal-title":"Mol Ther"},{"issue":"1","key":"30_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/mt.2010.212","volume":"19","author":"JK Kang","year":"2011","unstructured":"Kang JK, Malerba A, Popplewell L et al (2011) Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther 19(1):159\u2013164","journal-title":"Mol Ther"},{"key":"30_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-1-4939-8651-4_21","volume":"1828","author":"N Lu-Nguyen","year":"2018","unstructured":"Lu-Nguyen N, Dickson G, Malerba A (2018) Systemic intravenous administration of antisense therapeutics for combinatorial dystrophin and myostatin exon splice modulation. Methods Mol Biol 1828:343\u2013354","journal-title":"Methods Mol Biol"},{"issue":"18","key":"30_CR17","first-page":"3091","volume":"28","author":"N Lu-Nguyen","year":"2019","unstructured":"Lu-Nguyen N, Ferry A, Schnell FJ et al (2019) Functional muscle recovery following dystrophin and myostatin exon splice modulation in aged mdx mice. Hum Mol Genet 28(18):3091\u20133100","journal-title":"Hum Mol Genet"},{"key":"30_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtn.2016.11.009","volume":"6","author":"N Lu-Nguyen","year":"2017","unstructured":"Lu-Nguyen N, Malerba A, Popplewell L et al (2017) Systemic antisense therapeutics for dystrophin and myostatin exon splice modulation improve muscle pathology of adult mdx mice. Mol Ther Nucleic Acids 6:15\u201328","journal-title":"Mol Ther Nucleic Acids"},{"key":"30_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.54","volume":"1","author":"A Malerba","year":"2012","unstructured":"Malerba A, Kang JK, McClorey G et al (2012) Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of Duchenne muscular dystrophy. Mol Ther Nucleic Acids 1:e62","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"30_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm1242","volume":"11","author":"JE Davies","year":"2005","unstructured":"Davies JE, Wang L, Garcia-Oroz L et al (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 11(6):672\u2013677","journal-title":"Nat Med"},{"issue":"11","key":"30_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/hmg\/ddq098","volume":"19","author":"C Trollet","year":"2010","unstructured":"Trollet C, Anvar SY, Venema A et al (2010) Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet 19(11):2191\u20132207","journal-title":"Hum Mol Genet"},{"issue":"34","key":"30_CR22","doi-asserted-by":"publisher","first-page":"34ra40","DOI":"10.1126\/scitranslmed.3000723","volume":"2","author":"JE Davies","year":"2010","unstructured":"Davies JE, Rose C, Sarkar S et al (2010) Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci Transl Med 2(34):34ra40","journal-title":"Sci Transl Med"},{"issue":"6","key":"30_CR23","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/hmg\/ddq559","volume":"20","author":"JE Davies","year":"2011","unstructured":"Davies JE, Rubinsztein DC (2011) Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 20(6):1154\u20131163","journal-title":"Hum Mol Genet"},{"issue":"1","key":"30_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/hmg\/ddi422","volume":"15","author":"JE Davies","year":"2006","unstructured":"Davies JE, Sarkar S, Rubinsztein DC (2006) Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 15(1):23\u201331","journal-title":"Hum Mol Genet"},{"issue":"10","key":"30_CR25","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/hmg\/ddz007","volume":"28","author":"A Malerba","year":"2019","unstructured":"Malerba A, Roth F, Harish P et al (2019) Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. Hum Mol Genet 28(10):1694\u20131708","journal-title":"Hum Mol Genet"},{"key":"30_CR26","doi-asserted-by":"publisher","first-page":"14848","DOI":"10.1038\/ncomms14848","volume":"8","author":"A Malerba","year":"2017","unstructured":"Malerba A, Klein P, Bachtarzi H et al (2017) PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 8:14848","journal-title":"Nat Commun"},{"issue":"19","key":"30_CR27","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1093\/hmg\/ddz167","volume":"28","author":"A Malerba","year":"2019","unstructured":"Malerba A, Klein P, Lu-Nguyen N et al (2019) Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1. Hum Mol Genet 28(19):3301\u20133308","journal-title":"Hum Mol Genet"}],"container-title":["Methods in Molecular Biology","Muscular Dystrophy Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2772-3_30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T07:08:18Z","timestamp":1677654498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2772-3_30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"ISBN":["9781071627716","9781071627723"],"references-count":27,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_30","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"19 November 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}